Cells deficient in argininosuccinate synthetase (ASS) must absorb the arginine they need for growth from circulating blood. Treatment with pegylated arginine deiminase (ADI-PEG 20) selectively eliminates arginine from the circulation and has shown some efficacy against ASS-deficient tumors including small cell lung cancer (SCLC). We sought to assess ASS expression in a cohort of high-grade pulmonary neuroendocrine carcinomas (PNEC) which include SCLC and large cell neuroendocrine carcinoma (LCNEC).
Sixty-nine PNEC (49 SCLC and 20 LCNEC) were retrieved from our pathology archives. Formalin-fixed paraffin-embedded sections of the 54 primary tumors, 15 metastases and appropriate positive and negative controls were immunostained using an ASS-specific monoclonal antibody. Positive staining in <30 % of the tumor was scored as weak; staining in ≥30 % of the tumor was scored as strong. The absence of staining in the tumor was recorded as ASS negative.
58 % of the PNEC including 61.2 % of the SCLC and 50 % of the LCNEC were ASS negative. These ASS-negative tumors included 63 % of the primary and 40 % of the metastatic lesions tested.
More than 50 % of the high-grade PNEC tested lack immunohistochemically detectable ASS, suggesting that they are auxotrophic for arginine and potential candidates for arginine deprivation therapy. PNEC comprise about 25 % of primary lung cancers and have a 5-year overall survival of only 5–10 %, underscoring the need for new and more effective therapies. Immunostaining for ASS has potential to improve the selection of patients with PNEC for arginine deprivation therapy with ADI-PEG 20.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Abuchowski A, McCoy JR, Palczuk NC et al (1977a) Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J Biol Chem 252:3582–3586
Abuchowski A, van Es T, Palczuk NC et al (1977b) Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J Biol Chem 252:3578–3581
Allen MD, Luong P, Hudson C et al (2014) Prognostic and therapeutic impact of argininosuccinate synthetase 1 control in bladder cancer as monitored longitudinally by PET imaging. Cancer Res 74:896–907
Aoun P, Wiggins M, Pickering D et al (2004) Interphase fluorescence in situ hybridization studies for the detection of 9q34 deletions in chronic myelogenous leukemia: a practical approach to clinical diagnosis. Cancer Genet Cytogenet 154:138–143
Ascierto PA, Scala S, Castello G et al (2005) Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies. J Clin Oncol 23:7660–7668
Cerami E, Gao J, Dogrusoz U et al (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2:401–404
Cheon DJ, Walts AE, Beach JA et al (2014) Differential expression of ASS1 in serous and non-serous ovarian carcinomas. J Path: Clin Res. doi:10.1002/cjp2.4
Davis F (2002) The origin of pegnology. Adv Drug Deliv Rev 54:457–458
Ensor CM, Holtsberg FW, Bomalaski JS et al (2002) Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo. Cancer Res 62:5443–5450
Feun LG, Marini A, Walker G et al (2012) Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase. Br J Cancer 106:1481–1485
Fontenelle LJ, Henderson JF (1969) Sources of nitrogen as rate-limiting factors for purine biosynthesis de novo in Ehrlich ascites tumor cells. Biochim Biophys Acta 177:88–93
Gao J, Aksoy BA, Dogrusoz U et al (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 6:l1
Haines RJ (2011) PendletonLC, Eichler DC. Argininosuccinate synthetase: at the center of arginine metabolism. Int J Biochem Mol Biol 2:8–23
He W, Chen J, Zheng Y et al (2010) Lack of expression of arginionosuccinate synthetase in human cancer tissue: a biomarker for sensitivity to arginine depletion with pegylated arginine deiminase [abstract]. In: Proceedings of the 101st annual meeting of the American Association for Cancer Research, Apr 17–21; Washington, DC: AACR; 2010. Abstract #4703
Huang H-Y, Wu W-R, Wang Y-H et al (2013) ASS1 as a novel tumor suppressor gene in myxofibrosarcomas: aberrant loss via epigenetic DNA methylation confers aggressive phenotypes, negative prognostic impact, and therapeutic relevance. Clin Cancer Res 19:2861–2872
Izzo F, Marra P, Beneduce G et al (2004) Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies. J Clin Oncol 22:1815–1822
Jungbluth A, Tassello J, Frosina D et al (2010) Expression pattern of argininosuccinate-synthetase (ASS) in normal and tumor tissue as a marker for susceptibility to arginine-deiminase (ADI) therapy. Mod Pathol 23(Suppl1):387A
Kelly MP, Jungbluth AA, Wu BW et al (2012) Arginine deiminase PEG20 inhibits growth of small cell lung cancers lacking expression of argininosuccinate synthetase. Br J Cancer 106:324–332
Lan J, Tai HC, Lee SW et al (2014) Deficiency in expression and epigenetic DNA methylation of ASS1 gene in nasopharyngeal carcinoma: negative prognostic impact and therapeutic relevance. Tumour Biol 35:161–169
Long Y, Tsai WB, Wangpaichitr M et al (2013) Arginine deiminase resistance in melanoma cells is associated with metabolic reprogramming, glucose dependence, and glutamine addiction. Mol Cancer Ther 12:2581–2590
Phillips MM, Sheaff MT, Szlosarek PW (2013) Targeting arginine-dependent cancers with arginine-degrading enzymes: opportunities and challenges. Cancer Res Treat 45:251–262
Qiu F, Chen YR, Liu X et al (2004) (2104) Arginine starvation impairs mitochondrial respiratory function in ASS1-deficient breast cancer cells. Sci Signal 7(319):ra31. doi:10.1126/scisignal761
Shen LJ, Lin WC, Beloussow K, Shen WC (2003) Resistance to the anti-proliferative activity of recombinant arginine deiminase in cell culture correlates with the endogenous enzyme, argininosuccinate synthetase. Cancer Lett 191:165–170
Syed N, O’Neill K, Highes M et al (2011) Transcriptional silencing disrupts two levels of arginine biosynthesis in glioblastoma multiforme: a novel, targeted therapeutic strategy for high grade gliomas [abstract]. In: In: Proceedings of the 102nd annual meeting of the American Association for Cancer Research; 2011 Apr 2–6; Orlando, FL: AACR. Abstract #LB260
Synakiewicz A, Stachowicz-Stencel T, Adamkiewicz-Drozynska E (2014) The role of arginine and the modified arginine deiminase enzyme ADI-PEG 20 in cancer therapy with special emphasis on Phase I/II clinical trials. Expert Opin Investig Drugs 23:1–13
Szlosarek PW, Luong F, Clear A et al (2011) Pegylated aqrginine deiminase (ADI-PEG20) as a potential novel therapy for argininosuccinate synthetase-deficient acute myeloid leukemia. [abstract]. In: Proceedings of the 102nd annual meeting of the American Association for Cancer Research, Apr 2–6; Orlando, FL: AACR; 2011. Abstract #4067
Szlosarek PW, Steele JP, Nolan L et al (2014) Randomized trial of arginine deprivation with pegylated arginine deiminase in patients with malignant pleural mesothelioma. J Clin Oncol 32:5s (suppl; abstr 7507)
Szlosarek PW, Klabatsa A, Pallaska A et al (2006) In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion. Clin Cancer Res 12:7126–7131
Szlosarek PW, Luong P, Phillips MM et al (2013) Metabolic response to pegylated arginine deiminase in mesothelioma with promoter methylation of argininosuccinate synthetase. J Clin Oncol 31:e111–e113
Weich D, Li S, Kitchens T et al (2012) Arginine depravation therapy with arginine deiminase and autopohagy inhibition is a novel therapeutic approach for the treatment of metastatic sarcomas that lack argininosuccinate synthetsase expression [abstract]. In: Proceedings of the 103rd annual meeting of the American Association for Cancer Research, 2012 Mar 31–Apr 4; Chicago, IL: AACR; 2012. Abstract #5629
www.SEER.cancer.gov/statfacts/html/lungb.html [Web site]. http://www.SEER.cancer.gov/statfacts/html/lungb.html. Accessed Oct 21, 2014
Yang T-S, Lu S-N, Chao et al (2010) A randomized phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients. Br J Cancer 103:954–960
Yoon CY, Shim YJ, Kim EH et al (2007) Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivation via arginine deiminase. Int J Cancer 120:897–905
Conflict of interest
JSB is a stock owner and employee of the Polaris Group, Inc., which produces ADI-PEG 20. Other authors declare no conflicts of interest.
About this article
Cite this article
Walts, A.E., Bomalaski, J.S., Ines, D. et al. Argininosuccinate synthetase (ASS) deficiency in high-grade pulmonary neuroendocrine carcinoma: an opportunity for personalized targeted therapy. J Cancer Res Clin Oncol 141, 1363–1369 (2015). https://doi.org/10.1007/s00432-014-1904-z
- Argininosuccinate synthetase (ASS)
- Pegylated arginine deiminase (ADI-PEG20)
- Neuroendocrine carcinoma
- Small cell lung cancer
- Large cell neuroendocrine carcinoma